Sanofi-Aventis U.S. LLC is brandishing a recent U.S. Supreme Court decision to take aim at actions brought by nearly 70 women over its chemotherapy drug Taxotere.
The lawsuits are among more than 1,000 coordinated in federal court in New Orleans alleging that Taxotere, used to treat breast cancer, has caused women to lose their hair permanently. On Thursday, Sanofi filed notices citing the Supreme Court’s June 19 ruling in Bristol-Myers Squibb v. Superior Court of California to oppose the remand of 11 lawsuits to state courts in Missouri and California. In Bristol-Myers, the Supreme Court found that plaintiffs suing in California state court, most of whom weren’t from California, had failed to establish specific jurisdiction against New York-based Bristol-Myers Squibb.
